Brokerages forecast that Nuvectra Corp (NASDAQ:NVTR) will post $12.38 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Nuvectra’s earnings, with the highest sales estimate coming in at $12.57 million and the lowest estimate coming in at $12.18 million. Nuvectra reported sales of $7.62 million in the same quarter last year, which would suggest a positive year over year growth rate of 62.5%. The company is scheduled to report its next earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Nuvectra will report full-year sales of $50.48 million for the current financial year, with estimates ranging from $50.42 million to $50.54 million. For the next fiscal year, analysts forecast that the business will report sales of $74.14 million, with estimates ranging from $72.52 million to $75.76 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Nuvectra.

Nuvectra (NASDAQ:NVTR) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.11. Nuvectra had a negative return on equity of 77.95% and a negative net margin of 98.28%. The firm had revenue of $13.15 million during the quarter, compared to analyst estimates of $11.57 million.

Several research analysts have issued reports on NVTR shares. Zacks Investment Research upgraded Nuvectra from a “sell” rating to a “hold” rating in a research note on Friday, June 22nd. BidaskClub lowered Nuvectra from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 price objective on shares of Nuvectra in a research note on Wednesday, August 8th. Finally, JMP Securities increased their price objective on Nuvectra from $18.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.50.

In other news, President Joseph Paul Hanchin sold 1,250 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $20.43, for a total value of $25,537.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Several large investors have recently made changes to their positions in the company. First Manhattan Co. acquired a new stake in shares of Nuvectra in the second quarter valued at $102,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Nuvectra in the second quarter valued at $105,000. Essex Investment Management Co. LLC increased its stake in shares of Nuvectra by 3.8% in the third quarter. Essex Investment Management Co. LLC now owns 183,418 shares of the company’s stock valued at $4,032,000 after buying an additional 6,729 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in shares of Nuvectra in the second quarter valued at $148,000. Finally, Financial Architects Inc increased its stake in shares of Nuvectra by 300.0% in the second quarter. Financial Architects Inc now owns 10,000 shares of the company’s stock valued at $205,000 after buying an additional 7,500 shares in the last quarter. Institutional investors own 73.95% of the company’s stock.

Nuvectra stock traded down $1.23 during mid-day trading on Monday, hitting $20.79. 140,157 shares of the company were exchanged, compared to its average volume of 254,123. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.10 and a quick ratio of 3.77. Nuvectra has a 1-year low of $7.60 and a 1-year high of $25.17. The firm has a market capitalization of $314.02 million, a P/E ratio of -4.93 and a beta of -1.66.

About Nuvectra

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

Featured Story: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.